MYGN
MYRIAD GENETICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.89
−6.04%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- -$0.16
- Revenue estimate
- $191.4M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$0.25
- EPS estimate
- -$0.06
- Revenue actual
- $190.7M
- Revenue estimate
- $206.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +33.5%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $3.12
- PT range
- $2.00 – $4.00
- Analysts
- 5
0 Buy4 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.06 | -$0.25 | Miss -331.93% | $190.7M |
| May 5, 2026 | -$0.06 | -$0.09 | Miss -50.00% | $200.4M |
| Feb 23, 2026 | -$0.02 | $0.04 | Beat 300.00% | $209.8M |
| Nov 7, 2024 | $0.02 | $0.06 | Beat 215.79% | $213.3M |
| Feb 27, 2024 | $0.01 | $0.04 | Beat 214.22% | $196.6M |
| Aug 3, 2023 | -$0.10 | -$0.08 | Beat 20.00% | $183.5M |
| May 3, 2023 | -$0.19 | -$0.21 | Miss -10.53% | $181.2M |
| Feb 28, 2023 | -$0.16 | -$0.12 | Beat 25.00% | $177.8M |
| Nov 1, 2022 | -$0.06 | -$0.19 | Miss -216.67% | $156.4M |
| Aug 4, 2022 | $0.01 | $0.04 | Beat 300.00% | $179.3M |
| May 5, 2022 | -$0.05 | -$0.03 | Beat 40.00% | $164.9M |
| Feb 24, 2022 | -$0.02 | -$0.02 | Miss -14.29% | $160.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026